ETRADE Capital Management LLC trimmed its holdings in Hill-Rom Holdings, Inc. (NYSE:HRC) by 4.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,946 shares of the medical technology company’s stock after selling 412 shares during the period. ETRADE Capital Management LLC’s holdings in Hill-Rom were worth $1,001,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also bought and sold shares of the business. First Citizens Bank & Trust Co. grew its stake in Hill-Rom by 4.8% in the first quarter. First Citizens Bank & Trust Co. now owns 2,261 shares of the medical technology company’s stock valued at $227,000 after acquiring an additional 103 shares during the period. Signaturefd LLC grew its stake in Hill-Rom by 53.3% in the first quarter. Signaturefd LLC now owns 302 shares of the medical technology company’s stock valued at $30,000 after acquiring an additional 105 shares during the period. Johnson Investment Counsel Inc. boosted its position in shares of Hill-Rom by 1.5% during the fourth quarter. Johnson Investment Counsel Inc. now owns 8,047 shares of the medical technology company’s stock worth $914,000 after buying an additional 116 shares during the period. Point72 Hong Kong Ltd boosted its position in shares of Hill-Rom by 7.7% during the fourth quarter. Point72 Hong Kong Ltd now owns 1,698 shares of the medical technology company’s stock worth $193,000 after buying an additional 122 shares during the period. Finally, Municipal Employees Retirement System of Michigan boosted its position in shares of Hill-Rom by 1.1% during the fourth quarter. Municipal Employees Retirement System of Michigan now owns 12,390 shares of the medical technology company’s stock worth $1,407,000 after buying an additional 130 shares during the period. 85.90% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE HRC opened at $99.08 on Friday. The stock has a 50 day moving average price of $107.38 and a 200 day moving average price of $105.97. Hill-Rom Holdings, Inc. has a 52 week low of $72.29 and a 52 week high of $117.50. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.22 and a current ratio of 1.52. The stock has a market capitalization of $6.59 billion, a PE ratio of 45.45, a price-to-earnings-growth ratio of 1.16 and a beta of 0.75.
Hill-Rom (NYSE:HRC) last issued its quarterly earnings results on Friday, May 1st. The medical technology company reported $1.28 EPS for the quarter, beating the consensus estimate of $1.15 by $0.13. Hill-Rom had a return on equity of 22.60% and a net margin of 5.04%. The firm had revenue of $723.20 million during the quarter, compared to analysts’ expectations of $701.72 million. During the same period in the prior year, the firm posted $1.14 earnings per share. The business’s quarterly revenue was up 1.3% compared to the same quarter last year. As a group, research analysts forecast that Hill-Rom Holdings, Inc. will post 5.47 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Friday, June 19th will be paid a $0.22 dividend. The ex-dividend date is Thursday, June 18th. This represents a $0.88 annualized dividend and a yield of 0.89%. Hill-Rom’s dividend payout ratio is 17.32%.
Several research firms have recently weighed in on HRC. Barclays reaffirmed a “buy” rating and set a $125.00 price objective on shares of Hill-Rom in a research report on Tuesday, April 14th. Morgan Stanley reduced their price objective on Hill-Rom from $138.00 to $125.00 and set an “overweight” rating for the company in a research report on Friday, March 27th. UBS Group reduced their price objective on Hill-Rom from $130.00 to $125.00 and set a “buy” rating for the company in a research report on Monday, May 4th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $131.00 price objective on shares of Hill-Rom in a research report on Friday, January 24th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $122.33.
In other Hill-Rom news, insider Amy M. Dodrill sold 3,189 shares of the company’s stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $110.00, for a total value of $350,790.00. Following the sale, the insider now owns 1,389 shares in the company, valued at $152,790. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.65% of the stock is owned by corporate insiders.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Read More: What is meant by holder of record?
Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.